In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
Top Cited Papers
Open Access
- 1 September 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 95 (9), e1267-e1284
- https://doi.org/10.1212/wnl.0000000000010404
Abstract
Objective The Systemic Synuclein Sampling Study (S4) measured α-synuclein in multiple tissues and biofluids within the same patients with Parkinson disease (PD) vs healthy controls (HCs). Methods S4 was a 6-site cross-sectional observational study of participants with early, moderate, or advanced PD and HCs. Motor and nonmotor measures and dopamine transporter SPECT were obtained. Biopsies of skin, colon, submandibular gland (SMG), CSF, saliva, and blood were collected. Tissue biopsy sections were stained with 5C12 monoclonal antibody against pathologic α-synuclein; digital images were interpreted by neuropathologists blinded to diagnosis. Biofluid total α-synuclein was quantified using ELISA. Results The final cohort included 59 patients with PD and 21 HCs. CSF α-synuclein was lower in patients with PD vs HCs; sensitivity/specificity of CSF α-synuclein for PD diagnosis was 87.0%/63.2%, respectively. Sensitivity of α-synuclein immunoreactivity for PD diagnosis was 56.1% for SMG and 24.1% for skin; specificity was 92.9% and 100%, respectively. There were no significant relationships between different measures of α-synuclein within participants. Conclusions S4 confirms lower total α-synuclein levels in CSF in patients with PD compared to HCs, but specificity is low. In contrast, α-synuclein immunoreactivity in skin and SMG is specific for PD but sensitivity is low. Relationships within participants across different tissues and biofluids could not be demonstrated. Measures of pathologic forms of α-synuclein with higher accuracy are critically needed. Classification of evidence This study provides Class III evidence that total CSF α-synuclein does not accurately distinguish patients with PD from HCs, and that monoclonal antibody staining for SMG and skin total α-synuclein is specific but not sensitive for PD diagnosis.Keywords
This publication has 49 references indexed in Scilit:
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyThe Lancet Neurology, 2011
- Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with SymptomsPLOS ONE, 2010
- Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disordersActa Neuropathologica, 2010
- DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s diseaseBrain, 2010
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionActa Neuropathologica, 2009
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology, 2007
- Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson’s DiseaseBrain Pathology, 2007
- The Inconsistency of “Optimal” Cutpoints Obtained using Two Criteria based on the Receiver Operating Characteristic CurveAmerican Journal of Epidemiology, 2006
- Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUTMovement Disorders, 2004
- Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory functionPhysiology & Behavior, 1984